hC Bioscience
HC Bioscience is dedicated to transforming patients' lives through innovative tRNA-based therapeutics that target genetically defined diseases and cancer. Their platform utilizes engineered tRNAs to correct genetic mutations, enabling the production of full-length, functional proteins. The company's mission is to develop first-in-class therapies that address a broad spectrum of genetic disorders, with a focus on precision medicine and gene-agnostic approaches.
Industries
Nr. of Employees
small (1-50)
hC Bioscience
Cambridge, Massachusetts, United States, North America
Products
Liver-targeted anticodon-engineered tRNA candidate for restoration of Factor VIII
A development-stage anticodon-engineered tRNA delivered via lipid nanoparticle designed to suppress nonsense mutations in the Factor VIII transcript and restore synthesis of full-length, functional Factor VIII protein for severe hemophilia A.
Program applying anticodon-engineered tRNAs to Duchenne muscular dystrophy (PTC suppression)
Preclinical program delivering anticodon-engineered tRNAs to muscle cells to suppress premature termination codons in dystrophin mRNA and restore production of full-length dystrophin protein.
Oncology program to restore tumor suppressor proteins using engineered tRNAs
Preclinical tRNA-based oncology candidates designed to suppress nonsense mutations in tumor suppressor genes (e.g., APC) to restore full-length protein expression and inhibit tumor growth.
Liver-targeted anticodon-engineered tRNA candidate for restoration of Factor VIII
A development-stage anticodon-engineered tRNA delivered via lipid nanoparticle designed to suppress nonsense mutations in the Factor VIII transcript and restore synthesis of full-length, functional Factor VIII protein for severe hemophilia A.
Program applying anticodon-engineered tRNAs to Duchenne muscular dystrophy (PTC suppression)
Preclinical program delivering anticodon-engineered tRNAs to muscle cells to suppress premature termination codons in dystrophin mRNA and restore production of full-length dystrophin protein.
Oncology program to restore tumor suppressor proteins using engineered tRNAs
Preclinical tRNA-based oncology candidates designed to suppress nonsense mutations in tumor suppressor genes (e.g., APC) to restore full-length protein expression and inhibit tumor growth.
Services
Collaborative research and strategic partnerships for tRNA therapeutics
Collaborative R&D, platform access, and strategic partnering to co-develop or license tRNA-based therapeutics and delivery solutions.
Collaborative research and strategic partnerships for tRNA therapeutics
Collaborative R&D, platform access, and strategic partnering to co-develop or license tRNA-based therapeutics and delivery solutions.
Expertise Areas
- tRNA therapeutic discovery and engineering
- Delivery and formulation for nucleic acid therapeutics
- Preclinical in vivo pharmacology and tumor models
- CMC and downstream process development for polynucleotides
Key Technologies
- Anticodon-engineered tRNA therapeutics
- Lipid nanoparticle (LNP) delivery
- High-throughput tRNA sequencing and modification profiling (MSR-seq-style)
- Conjugate-based extra-hepatic delivery approaches